|
|
Volumn 17, Issue 6, 2012, Pages 533-
|
|
Drug-induced interstitial lung disease (DILD) in molecular targeted therapy
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CORTICOSTEROID;
ERLOTINIB;
GEFITINIB;
CANCER CHEMOTHERAPY;
DRUG EFFICACY;
DRUG SAFETY;
EDITORIAL;
HUMAN;
INCIDENCE;
INTERSTITIAL LUNG DISEASE;
JAPANESE;
LUNG NON SMALL CELL CANCER;
MOLECULARLY TARGETED THERAPY;
PRIORITY JOURNAL;
RISK ASSESSMENT;
ANTINEOPLASTIC AGENTS;
HUMANS;
LUNG DISEASES, INTERSTITIAL;
LUNG NEOPLASMS;
MOLECULAR TARGETED THERAPY;
|
|
EID: 84880701743
PISSN: 13419625
EISSN: 14377772
Source Type: Journal
DOI: 10.1007/s10147-012-0495-4 Document Type: Editorial |
|
Times cited : (3)
|
|
References (0)
|
